Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1405 participants.
Also called NCT01422876
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,405 participants
- Registry
-
NCT01422876 -
2011-000383-10
-
- Other papers using this trial's data
- Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin
- Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes
- Safety and Tolerability of Combinations of Empagliflozin and Linagliptin in Patients with Type 2 Diabetes: Pooled Data from Two Randomized Controlled Trials
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Brazil, Bulgaria, Canada, Colombia, Denmark, Estonia, Hungary, Italy, Lebanon, Malaysia, Mexico, Peru, Philippines, Poland, Romania, Russia, Spain, Sweden, Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT01422876. Randomized; double masking; primary purpose treatment. Start 2011-08 (registry gives no type); primary completion 2013-09 (actual). Results posted on 2015-04-02.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- high dose FDC
- Intervention (Drug)
- BI 10773 high dose
- Intervention (Drug)
- high dose FDC placebo
- Intervention (Drug)
- low dose FDC placebo
- Intervention (Drug)
- high dose FDC placebo
- Intervention (Drug)
- high dose FDC placebo
- Intervention (Drug)
- low dose FDC placebo
- Intervention (Drug)
- low dose FDC placebo
- Intervention (Drug)
- high dose BI 10773 placebo
- Intervention (Drug)
- low dose FDC
- Intervention (Drug)
- high dose FDC placebo
- Intervention (Drug)
- BI 10773 low dose
- Intervention (Drug)
- high dose BI 10773 placebo
- Intervention (Drug)
- high dose BI 10773 placebo
- Intervention (Drug)
- linagliptin
- Intervention (Drug)
- low dose FDC placebo
- Intervention (Drug)
- linagliptin placebo
- Intervention (Drug)
- BI 10773 low dose placebo
- Intervention (Drug)
- linagliptin placebo
- Intervention (Drug)
- low dose BI 10773 placebo
- Intervention (Drug)
- linagliptin placebo
- Intervention (Drug)
- high dose BI 10773 placebo
- Intervention (Drug)
- BI 10773 low dose placebo
- Intervention (Drug)
- low dose BI 10773 placebo
- Intervention (Drug)
- linagliptin placebo
- Lead sponsor
- Boehringer Ingelheim
- Collaborator
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct01422876- Content hash
167e2d188719d6353b5b778c02e038282dc9bdb33d6037f153690511e471bea6